Testing a new drug for active lung sarcoidosis
Part of Blood & lymphatic, Immune system & allergy, Lungs & breathing clinical trials.
This study tests a new medication, OATD-01, for people with active sarcoidosis in their lungs. It aims to see how safe and effective the drug is and if it can improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active sarcoidosis in your lungs that is causing symptoms like cough or shortness of breath.
- You have not had sarcoidosis that spreads to your heart or brain.
- You have not taken steroids in the last 3 months, or other stronger medications in the last 4 months.
- You do not have other major lung diseases like asthma, COPD, or lung cancer.
- Your heart function is good, with no significant arrhythmia or heart failure.
- You are a nonsmoker or smoke less than 5 cigarettes or e-cigarettes per day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug to see if it can help people with pulmonary sarcoidosis, which affects the lungs. The drug may work by reducing inflammation, and this study will check its safety and effectiveness.
This trial tests an experimental drug called XTMAB-16 for people with sarcoidosis in the lungs, which may also affect other parts of the body. The goal is to see if it helps improve breathing and reduce symptoms.
This trial studies a treatment approach for people with active cardiac sarcoidosis, confirmed by specific heart rhythm/heart function problems and a PET scan. It may help by targeting the active inflammation driving heart conduction problems, rhythm events, or weak heart pumping.
This trial tests a steroid medication called compound betamethasone for people with newly diagnosed pulmonary sarcoidosis (stage I or II). It may help reduce inflammation and improve symptoms compared to standard prednisone treatment.
This trial tests whether nintedanib, a drug that slows lung scarring, can help people with sarcoidosis-related lung fibrosis. It is for those who still have breathlessness or cough despite stable treatment.
This study tests whether a tracing agent called tilmanocept can help doctors see inflammation in the heart caused by sarcoidosis. It may provide a new way to diagnose and monitor cardiac sarcoidosis without invasive procedures.
Hear when a new Pulmonary Sarcoidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.